This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!
Adam Feuerstein's Biotech Blog

Adam Feuerstein's Biotech Blog

Adam Feuerstein

Adam Feuerstein investigates the highly-speculative world of biotech stocks, and helps biotech investors avoid losing money.

To participate in Adam's "Biotech Stock Mailbag," please send your questions or comments using this form.

To chat with Adam on Twitter, click here.

Biotech Blog

Express Scripts and CVS Caremark are the largest and second-largest pharmacy benefits managers in the U.S. Both have been aggressive with efforts to rein in ever-escalating drug prices.
7/28/14 10:56AM
AcelRx believes it can gather all the requested information and re-submit Zalviso to the FDA before the end of the year.
7/28/14 9:44AM
MannKind must report second-quarter financials before the end of the second week in August, which sets a quasi-deadline for Afrezza partner plans.
7/25/14 11:30AM
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
7/25/14 7:31AM
Sarepta terminates Chief Scientific Officer Art Krieg. Here's what I've learned about why he was fired.
7/24/14 9:21AM
In its first two quarters on the market, Sovaldi, a pill used to treat hepatitis C, has delivered $5.8 billion in revenue to Gilead. Remarkable.
7/23/14 5:44PM
Puma is why so many investors love to speculate on biotech stocks. A contrarian trade against a heavily expected outcome can return a fortune.
7/23/14 12:26PM
Inovio's analysis of the VGX-3100 study omits an unknown number of patients, calling the results into question.
7/23/14 10:17AM
The buyside "whisper number" for Sovaldi sales is $3.5 billion. But everyone who follows Gilead knows this, which means the "whispered" whisper number for sales is $4 billion or more.
7/22/14 12:12PM
Galena stands little chance of delivering higher sales of Zuplenz than its previous marketer.
7/22/14 9:41AM
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
7/18/14 7:51AM
Biotech indices plunge on cautious remarks made by Fed Chairwoman during Congressional testimony.
7/15/14 1:10PM
Healthcare investor David Miller believes Roche will likely acquire Exelixis in order to capture the full economics of the cancer drug cobimetinib.
7/14/14 11:14AM
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
7/14/14 9:30AM
Roche intends to seek U.S. approval for cobimetinib later this year.
7/14/14 7:46AM
Healthcare investors (and traders) have had a lot to work with so far this year, and the next six months promises to be equally action packed.
7/10/14 11:54AM
Even with greater decline in walk performance after almost three years, Duchenne boys treated with eteplirsen are still benefiting from treatment, Sarepta says.
7/10/14 8:31AM
The SEC halts trading in Radient Pharmaceuticals.
7/8/14 9:52AM
Provectus Biopharmaceuticals issued a "CEO Letter" Tuesday regurgitating all the recent spin and ridiculously unrealistic talking points about the company's experimental (but already obsolete) melanoma therapy PV-10.
7/8/14 9:14AM
Sarepta is selling off Monday on new worries about eteplirsen efficacy. Of course, these are really just old worries, recycled.
7/7/14 2:49PM
Lief's $1.3 million sale of Arena shares was disclosed in an SEC filing last week.
7/7/14 11:23AM
The hip waders I normally wear for protection from biotech bullshit aren't tall enough to wade through Ampio's current press release. I need a full haz-mat suit.
6/25/14 1:05PM
Investors aren't yet recognizing Vertex's ability to develop triple-combo therapies for hardest-to-treat cystic fibrosis patients.
6/25/14 11:26AM
A phase II study of Squalamine in wet age-related macular degeneration bombed badly.
6/24/14 12:07PM

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,914.91 -45.66 -0.27%
S&P 500 1,970.82 -7.52 -0.38%
NASDAQ 4,424.6210 -24.9430 -0.56%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs